Kurt J. Hilzinger, Director at Outlook Therapeutics, Inc. (OTLK), bought 350,264 shares at $1.44 ($514K) on 2022-02-23, disclosed to the SEC on 2022-02-23.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.49 | 95,597 | $142K | 27.7% |
| 2 | $1.49 | 95,597 | $142K | 27.7% |
| 3 | $1.44 | 79,535 | $115K | 22.3% |
| 4 | $1.44 | 79,535 | $115K | 22.3% |
| Total | $1.47 avg | 350,264 | $514K | 100% |
| Filing → |
| OTLK | BUY | 2022-10-03 | $163K | — | Filing → |
| OTLK | BUY | 2022-03-03 | $47K | — | Filing → |
| OTLK | BUY | 2022-02-28 | $130K | — | Filing → |